Myelodysplastic Syndromes Clinical Trials

74 studies are recruiting for myelodysplastic syndromes in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

   The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecul…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT04742634 on ClinicalTrials.gov

2. Ascorbate in Myelodysplastic Syndrome

   This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.

   Stage

   Phase 2

   Ages

   18 to 99

   Site

   University of Iowa, Iowa City, Iowa

   Run by

   Prajwal Dhakal

   See if you can join NCT07283900 on ClinicalTrials.gov

3. Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

   The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for treatment of hematologic malignances with Fludarabine and Melphalan.

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT07044544 on ClinicalTrials.gov

4. Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

   The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sylvester Comprehensive Cancer Center, Miami, Florida

   Locations

   3 in total

   Run by

   University of Miami

   See if you can join NCT05745285 on ClinicalTrials.gov

5. Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

   This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune…

   Stage

   Phase 2

   Ages

   Up to 65

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT03579875 on ClinicalTrials.gov

6. Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

   This is a Phase 1b, open-label study evaluating Venetoclax in combination with intensive induction and consolidation chemotherapy in previously untreated, adult patients with acute myeloid leukemia. In Part 1, the dose escalation phase, the safety and tolerability of the combination with Venetoclax…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM), The Bronx, New York

   Run by

   Montefiore Medical Center

   See if you can join NCT05342584 on ClinicalTrials.gov

7. Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

   Myeloid malignancies which include AML (acute myeloid leukemia) and MDS (myelodysplatic syndrome) are cancers of the bone marrow which lead to bone marrow failure. The bone marrow is the place or factory in the body where components of blood such as red cells, platelets and white cells are made. In…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California Davis Health (UC Davis Health), Sacramento, California

   Locations

   3 in total

   Run by

   Montefiore Medical Center

   See if you can join NCT05184842 on ClinicalTrials.gov

8. Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

   This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Jacksonville, Florida

   Locations

   7 in total

   Run by

   Syntrix Biosystems, Inc.

   See if you can join NCT04245397 on ClinicalTrials.gov

9. Home Blood Transfusions

   This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic malignancies and other bone marrow failure syndromes who are transfusion dependent and interested in a home blood transfusion program. Parti…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07121140 on ClinicalTrials.gov

10. Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

    This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for pat…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT05434598 on ClinicalTrials.gov

11. Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

    This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 …

    Stage

    Phase 2

    Ages

    10 to 30

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    3 in total

    Run by

    Children's Hospital of Philadelphia

    See if you can join NCT05194397 on ClinicalTrials.gov

12. Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

    This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Montefiore Medical Center, The Bronx, New York

    Locations

    2 in total

    Run by

    Montefiore Medical Center

    See if you can join NCT05986240 on ClinicalTrials.gov

13. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Birmingham, Alabama

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

14. Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

    RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic c…

    Stage

    Not phased

    Ages

    18 to 120

    Site

    Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT01137643 on ClinicalTrials.gov

15. IS-free Treg HaploHCT

    This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory and Ultra-high risk acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) receiving a haploidentical donor allogeneic hematopo…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04678401 on ClinicalTrials.gov

16. Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

    This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for pat…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT04986657 on ClinicalTrials.gov

17. Umbilical Cord Blood Transplantation From Unrelated Donors

    This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-fr…

    Stage

    Not phased

    Ages

    0 to 75

    Site

    Wilmot Cancer Institute, Rochester, New York

    Run by

    University of Rochester

    See if you can join NCT03016806 on ClinicalTrials.gov

18. Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

    The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug called (rabbit Anti-thymocyte Globulin [ATG]) will help prevent the development and/or improve severity of acute and/or chronic GVHD.

    Stage

    Phase 2

    Ages

    18 to 60

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT06315309 on ClinicalTrials.gov

19. A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

    Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the sa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    13 in total

    Run by

    BlossomHill Therapeutics

    See if you can join NCT06501196 on ClinicalTrials.gov

20. HEME Home Transfusion Program

    This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancie…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06487247 on ClinicalTrials.gov

21. Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform

    The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, to * expand the understanding of SD…

    Stage

    Not phased

    Ages

    Any age

    Site

    Shwachman-Diamond Syndrome Alliance Inc., Woburn, Massachusetts

    Run by

    Shwachman-Diamond Syndrome Alliance Inc

    See if you can join NCT06999954 on ClinicalTrials.gov

22. Study of REM-422 in Patients With AML or Higher Risk MDS

    The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    9 in total

    Run by

    Remix Therapeutics

    See if you can join NCT06297941 on ClinicalTrials.gov

23. Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

    The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will b…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    5 in total

    Run by

    Tr1X, Inc.

    See if you can join NCT06462365 on ClinicalTrials.gov

24. A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

    The purpose of this study is to test the safety and efficacy (benefits) of an investigational drug LB-100, for treatment of myelodysplastic syndromes. LB-100 has previously been administered to patients with various solid tumors. In this study, LB-100 will be administered as an intravenous infusion…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

    Run by

    Lixte Biotechnology Holdings, Inc.

    See if you can join NCT03886662 on ClinicalTrials.gov